Literature DB >> 3027568

Elevated levels of diacylglycerol and decreased phorbol ester sensitivity in ras-transformed fibroblasts.

A Wolfman, I G Macara.   

Abstract

Diacylglycerol (DG) plays a central role in phospholipid metabolism and is an endogenous activator of protein kinase C. We have suggested that constitutive activation of this kinase is one mechanism by which oncogenes transform cells. The ras-encoded proteins are similar to regulatory G-proteins and are candidates for the unknown G-protein that modulates phosphatidylinositol (PI) turnover. Differences in polyphosphoinositide metabolism have been reported for ras-transformed cells. But because these experiments were performed on confluent cultures of established cell lines, the differences are difficult to attribute to ras transformation. Here we show that exponentially growing NIH 3T3 fibroblasts recently transformed by Ha-ras or Ki-ras possess elevated DG concentrations without significant alterations in the levels of other polyphosphoinositide metabolites. The basal phosphorylation of protein kinase C substrate of relative molecular mass (Mr) 80,000 (80K) is significantly increased in all the ras-transformed cell lines. Surprisingly, however, further phosphorylation of this protein on addition of phorbol ester was greatly reduced. Ha-ras cells also show less binding of phorbol ester than control cells, suggesting that elevation of DG causes partial down-regulation in addition to activation of protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3027568     DOI: 10.1038/325359a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  82 in total

1.  Transcription induction of c-Ki-ras with the tumour promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) in normal and transformed liver cells.

Authors:  S O Chan; S S Wong; D C Yeung
Journal:  Mol Cell Biochem       Date:  1992-11-04       Impact factor: 3.396

2.  Transformation stimulates glucose transporter gene expression in the absence of protein kinase C.

Authors:  Y Hiraki; A Garcia de Herreros; M J Birnbaum
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

3.  Induction of the metastatic phenotype by transfection of the nuclear oncogene p53: increases in cytoplasmic diacylglycerol levels and reduction in class I major histocompatibility antigen expression are not sufficient to explain the changes in metastatic capacities.

Authors:  J Pohl; V Lehmann; A Radler-Pohl; V Schirrmacher
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene.

Authors:  G Brunner; J Pohl; L J Erkell; A Radler-Pohl; V Schirrmacher
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

5.  Transfection of insulin-producing cells with a transforming c-Ha-ras oncogene stimulates phospholipase C activity.

Authors:  P O Berggren; A Hallberg; N Welsh; P Arkahammar; T Nilsson; M Welsh
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

6.  Protein turnover in 3T3 cells transformed with the oncogene c-H-ras1.

Authors:  J M Gunn; G James
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

Review 7.  Structural basis of protein kinase C isoform function.

Authors:  Susan F Steinberg
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

8.  Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose.

Authors:  P A Craven; F R DeRubertis
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

Review 9.  Therapeutic potential of protein kinase C inhibitors.

Authors:  D Bradshaw; C H Hill; J S Nixon; S E Wilkinson
Journal:  Agents Actions       Date:  1993-01

Review 10.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.